OverviewChartNewsTraderScreen

Morgan Stanley Call 135 NOVN 19.1.../  DE000MG4JPR2  /

Stuttgart
9/9/2024  5:37:10 PM Chg.+0.007 Bid10:00:34 PM Ask10:00:34 PM Underlying Strike price Expiration date Option type
0.099EUR +7.61% -
Bid Size: -		 -
Ask Size: -		 NOVARTIS N 135.00 CHF 12/19/2025 Call
TeleTrader 7/18 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 6/26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 6/13 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
TeleTrader 5/2 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 4/23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 4/23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 4/16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 4/11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 4/9 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 3/14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 3/12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 2/28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TeleTrader 2/5 Novartis to acquire MorphoSys for $2.9B
TeleTrader 1/31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 1/10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 1/5 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 1/2 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 12/21/2023 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 12/19/2023 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 12/11/2023 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 12/8/2023 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 12/6/2023 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 11/28/2023 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 11/20/2023 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH